Emcure Pharmaceuticals announced robust financial results for the second quarter and half-year ended September 30, 2026. Revenue grew by 24.3% year-on-year to INR 28,205 million, while Profit After Tax (PAT) increased by 29.3% to INR 3,251 million. The company highlighted broad-based growth across its domestic and international segments, driven by productivity gains and operating leverage, expecting this momentum to continue.
Emcure Pharmaceuticals Reports Strong Q2 FY27 Performance
Emcure Pharmaceuticals Limited has announced its consolidated financial results for the second quarter (Q2) and the first half (H1) of the fiscal year 2027, ending on September 30, 2026. The company demonstrated significant growth, with revenue from operations reaching INR 28,205 million, marking a 24.3% increase year-on-year. This performance reflects broad-based growth across its key markets.
Key Financial Highlights
For the second quarter, Emcure Pharmaceuticals reported a 29.3% rise in Profit After Tax (PAT) to INR 3,251 million. The Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) also saw a substantial increase of 30.9%, reaching INR 5,748 million. The EBITDA margin expanded to 20.4%, an improvement of approximately 100 basis points, attributed to enhanced productivity and operating leverage.
Segment Performance
The domestic business contributed INR 11,553 million to the revenue, showing a growth of 12.0%. The international business reported a robust growth of 34.5%, amounting to INR 16,652 million. This international growth was broad-based across Europe, Canada, and the Rest of the World, driven by continued expansion and new product launches. Notably, R&D investments stood at INR 1,110 million, representing about 4% of revenue.
Outlook and Strategic Updates
Satish Mehta, Chairman, Managing Director, and CEO of Emcure Pharmaceuticals, expressed optimism about the company’s trajectory. He stated, “Q2 was another strong quarter for Emcure, with broad-based growth in revenue, profitability and earnings.” The company anticipates that this business momentum will be sustained into the second half of FY27. In terms of corporate structure, the Board approved a draft scheme of amalgamation for its wholly-owned subsidiaries Zuventus Healthcare Limited and Emcutix Biopharmaceuticals Limited with Emcure Pharmaceuticals Limited, aimed at simplifying the group structure.
Source: BSE
